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Lyme Disease 
Lyme Borreliosis, 
 Lyme Arthritis, 
 Erythema Migrans  
with Polyarthritis 
 






Lyme disease is a tickborne illness that results from infection with members of 
the Borrelia burgdorferi sensu lato complex. These organisms are maintained in 
wild animals, but they can affect humans and some species of domesticated 
animals. Lyme disease was first recognized in the 1970s, when a cluster of juvenile 
arthritis cases was investigated in the U.S., but its symptoms can be found in 
European historical records as far back as the early 20th century. This disease has 
also been detected in Australia, parts of Asia, the province of Ontario, Canada, and 
recently, the Amazon region of Brazil. Lyme disease in people is readily cured with 
antibiotics during the initial stage of the illness, when an unusual rash often aids 
disease recognition. However, people whose infections remain untreated sometimes 
develop chronic arthritis, neurological signs and other syndromes. Lyme disease in 
domesticated animals is still poorly understood, and no distinctive rash seems to 
occur. The illness is best characterized in the dog, where arthritis and nephropathy 
appear to be the most common sequelae. Clinical signs attributed to Lyme disease 
have also been reported in other species including horses and cattle. 
Etiology 
Lyme disease results from infection by members of the Borrelia burgdorferi 
sensu lato complex, in the family Spirochaetaceae. There are more than a dozen 
recognized genospecies (genomic groups) in this complex, but some of them do not 
seem to be pathogenic in people or domesticated animals. Genospecies known to 
cause Lyme disease in humans include B. burgdorferi sensu stricto, B. garinii, B. 
afzelii and the recently recognized species B. spielmanii. B. bissettii, B. lusitaniae and 
B. valaisiana may also be pathogenic, based on their isolation from Lyme disease 
patients in Europe or Asia, and/or studies in laboratory animals. Each genospecies in 
the B. burgdorferi sensu lato complex may cause a somewhat different syndrome. In 
some genospecies, a few genetic groups appear to be associated with disseminated 
forms of the illness, while others are associated only with skin lesions. B. garinii, 
which circulates in both mammalian and avian reservoir hosts, is sometimes divided 
into “bird related” and “mammal or human related strains.” However, the isolate 
found in seabird ticks is nearly identical to some isolates from humans with Lyme 
disease, and the validity of this division has been questioned.  
B. burgdorferi s.l. has also been divided into eight serotypes, with B. 
burgdorferi sensu stricto corresponding to serotype 1, B. afzelii corresponding to 
serotype 2, and B. garinii containing serotypes 3 to 8.  
Genospecies in the B. burgdorferi s.l. complex that are not known to cause 
illness include B. andersonii, B. carolinensis and B. americana, which occur in 
North America, and B. japonica, B. tanukii, B. turdi and B. sinica in Asia. Several 
new genospecies (including B. carolinensis and B. americana) were identified 
recently in wild animals. Other species of Borrelia, which cause relapsing fever and 
other conditions, can cross-react with B. burgdorferi s.l. in serological tests. 
Geographic Distribution 
Lyme disease has been reported in North America, Europe, Australia and parts of 
Asia. Until recently, the organism was not thought to be endemic in South or Central 
America, although there have been isolated reports of human illness from Brazil, 
Mexico and Colombia. However, B. burgdorferi s.l. was recently confirmed to cause 
endemic cases of Lyme disease in the Amazon region of Brazil. Most of the 
organisms that cause Lyme disease occur in temperate regions because their vectors, 
Ixodes ticks, can survive only in these climates. B. garinii, which can infect both 
mammalian ticks and the seabird tick I. uriae, is an exception. I. uriae has a wide 
distribution that includes both polar and temperate regions in the Northern and 
Southern Hemispheres, and B. garinii has been detected in Alaska, the Antarctic, the 
Faroe Islands and Iceland. One study reported the occurrence of this genospecies in 
seabird ticks from Gull Island, Newfoundland, but not at other North American 
seabird nesting sites (Maine, Newfoundland and Labrador) on the Atlantic coast. 
Whether organisms in seabird ticks can be transmitted to people is still uncertain.  
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Each genospecies varies in its distribution. In North 
America, Lyme disease results from infection by B. 
burgdorferi sensu stricto. Although Lyme disease has been 
reported throughout the U.S., the major endemic foci are in 
the northeastern and mid-Atlantic states, along the Pacific 
coast and in the north-central U.S. B. burgdorferi s.l. is also 
endemic in Ontario, Canada. B. bissettii, which has been 
linked uncommonly to Lyme disease in Europe, occurs in 
North America, but it has not been associated with Lyme 
disease in this location.  
In Europe, several genospecies can cause Lyme 
disease. B. afzelii is the most common species in northern 
Europe, while B. burgdorferi s.s. has been reported mainly 
in western Europe. B. lusitaniae occurs in the 
Mediterranean basin, and seems to be more common than 
other genospecies in this region. A low prevalence of this 
organism may be found focally in other countries. B. 
spielmanii has been detected in Germany, France, the 
Netherlands, Hungary, Slovenia, Ukraine and other 
countries. B. valaisiana has been detected in a number of 
countries in mainland Europe and in the U.K., as well as 
in Russia.  
In Asia, Lyme disease is mainly caused by B. garinii 
and B. afzelii. B. burgdorferi s.s. has been detected in 
Taiwan. B. bissettii, B. valaisiana and B. lusitaniae have 
also been found in Asian countries.  
Within endemic areas, the prevalence of the infection 
in ticks, humans and animals can be highly focal. For 
example, one study detected antibodies to B. burgdorferi 
s.l. in 100% of the dogs in one small area of Maine, but in 
only 2% of the dogs in a nearby region. Migratory 
songbirds can distribute infected tick vectors during their 
spring migration, sometimes spreading the organisms 
beyond their usual geographic range.  
Transmission 
Members of the B. burgdorferi s.l. complex cycle 
between tick vectors and wild animal reservoir hosts in 
endemic areas. The organisms in this complex are 
transmitted by 3-host hard ticks in the genus Ixodes. B. 
burgdorferi s.s. is transmitted mainly by Ixodes scapularis 
(the deer tick; formerly I. dammini) in the eastern and 
midwestern U.S., and by I. pacificus (the Western black-
legged tick) on the Pacific coast. Other important vectors 
for the B. burgdorferi s.l. complex include I. ricinus (the 
sheep tick or forest tick) in Europe, and I. persulcatus (the 
taiga tick) in Asia and parts of Europe. B. garinii, which is 
transmitted by I. ricinus and I. persulcatus, can also be 
transmitted between seabirds by I. uriae, the seabird tick. I. 
uriae has occasionally been found on seals, river otters, 
humans and other mammals. B. burgdorferi s.l. also occurs 
in some ticks that, due to their preferred ecological niche, 
rarely bite humans. For example, this organism is found in 
some ticks, known as nidiculous ticks, which live mainly in 
the burrows, nests or caves of their hosts. Many 
genospecies of Borrelia can circulate in a region, and ticks 
can have mixed infections. Other insects such as flies, 
mosquitoes and fleas could be involved in spreading the 
organism via blood, but there is no evidence that these 
arthropods are important vectors. 
Ixodes ticks are widely distributed and feed on a 
variety of large and small mammals, birds and reptiles. 
These ticks are usually found in areas where the relative 
humidity is high at ground level. Reservoir hosts for B. 
burgdorferi s.l. are defined as those animals that can infect 
a significant number of the ticks that feed on them, 
Depending on the genospecies of Borrelia, they may 
include small mammals, birds and even some reptiles. Deer 
are not competent reservoir hosts, but they are important in 
maintaining tick populations by supplying a blood meal. 
Reservoir hosts are critical in maintaining Lyme disease in 
an area. Adult ticks may transmit B. burgdorferi 
transovarially to a very small percentage of the eggs, but 
the agent diminishes or disappears as the eggs develop into 
larvae and nymphs. For this reason, ticks must become 
infected (or reinfected) from a vertebrate reservoir host, and 
larvae (which have not yet fed) are rarely infected. 
However, transstadial transmission does occur. Before a 
tick can transmit the organism to a new host, it must remain 
attached for some time. During this lag phase, the surface 
proteins on the spirochete become adapted to the vertebrate 
host, in response to signals from the tick host and the blood 
meal. Transmission is always more likely with longer 
attachment, but the lag period seems to vary with the 
genospecies. B. burgdorferi s.s. is not usually transmitted 
before the tick has been attached for 48 hours, while B. 
afzelii can be acquired with an attachment period of less 
than 24 hours. The minimum attachment period is unknown 
for some genospecies. Domesticated animals and humans 
are incidental hosts, and become infected when they are 
bitten by ticks. Humans in the U.S. usually become infected 
by nymphs, which are very small (the size of a poppy seed) 
and may be overlooked long enough to transmit the 
organism. Dogs are more likely to be infected by adult 
ticks. 
B. burgdorferi s.l. is not thought to be transmitted via 
body fluids or the environment, although it has been 
reported occasionally in blood, urine, the breast milk of 
humans with erythema migrans, and colostrum or milk 
from cattle. This organism has been reported to survive for 
28 to 35 days in guinea pig blood at room temperature, for 
up to 48 days in human blood processed for transfusion and 
held at 4°C, and for short periods in urine. There are no 
known cases of Lyme disease resulting from a blood 
transfusion or contact with infected blood or urine in 
humans, although transfusion-acquired disease is 
theoretically possible: B. burgdorferi s.s. can be transmitted 
by blood transfusion in experimentally infected mice. In 
dogs, one case of horizontal transmission was reported from 
an experimentally infected to a control animal. In another 
study, seroconversion was not reported when uninfected 
and infected dogs were co-housed for a year. 
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Disinfection 
Borrelia burgdorferi s.l. can be inactivated by 1% 
sodium hypochlorite and 70% ethanol. It is also sensitive to 
heat and ultraviolet light. This organism does not survive 
well outside the body. 
Infections in Humans 
Incubation Period 
The incubation period in humans is typically 7 to 14 
days, but can vary from one to 36 days. 
Clinical Signs 
Both asymptomatic and symptomatic infections are 
seen in people. Each genospecies tends to be associated 
with particular syndromes, and somewhat different 
clinical presentations may occur in different geographic 
areas. The disease is more variable in Europe, where 
several pathogenic genospecies can be found, than in 
North America. 
In clinical cases, the first sign is usually a characteristic 
skin lesion called erythema migrans. In erythema migrans, a 
macule or papule widens and develops into a red or bluish-
red rash that expands over days or weeks. Its borders are 
usually distinct and often intensely colored (e.g., bright 
red), but not raised. The rash often, but not always, takes 
the form of a “bull’s-eye” with central clearing. 
Occasionally there may be vesicular or necrotic lesions in 
the center. Erythema migrans is ordinarily painless, but 
itching is possible. Secondary erythema migrans lesions 
sometimes appear in other areas. A small number of 
patients infected with B. afzelii or B. garinii develop a 
Borrelia lymphocytoma at the site of the tick bite. This 
lesion appears as a painless bluish-red or reddish-purple 
nodule or plaque, most often on the ear, nipple, or scrotum, 
but also on the nose, arms or other areas. It often occurs 
concurrently with erythema migrans, and is more common 
in children than adults. Borrelia lymphocytoma is very rare 
in North America. Lyme disease skin lesions may be 
accompanied by a flu-like illness with malaise, fatigue, 
fever, headache, a stiff neck, myalgia, arthralgia and/or 
regional lymph-adenopathy. Approximately 10-20% of 
infected people do not develop erythema migrans; some 
may have no early symptoms while others develop only 
nonspecific systemic signs. The initial symptoms of Lyme 
disease usually last a few weeks (Borrelia lymphocytoma 
can persist for months) and may recur. These signs 
eventually disappear even without treatment.  
Weeks or months later, some people may develop 
additional symptoms. The frequency of the various 
syndromes varies with the organism. Arthritis is especially 
common in B. burgdorferi s.s. infections, and it is seen 
more often in North American than Europe. It usually 
occurs as intermittent pain of one or a few joints, with or 
without swelling; large, weight-bearing joints such as the 
knee are most often affected. Arthritis may be recurrent or 
long lasting; it may persist for months or possibly years if 
not treated. Neurologic signs can be seen with all 
organisms, but especially B. garinii. They may include 
meningitis, facial palsy, radiculitis (pain or discomfort 
associated with nerve inflammation) or lymphocytic 
meningoradiculitis with or without paresis, as well as less 
common or rare syndromes such as myelitis, cranial 
neuritis, chorea or encephalitis. The specific neurological 
signs vary with the organism. Acute symptoms such as 
facial nerve palsy are usually self-limiting, but some signs 
can persist for months and sequelae are possible. Cardiac 
signs. with palpitations, lightheadedness and chest pain may 
be seen in 4-8% of patients in the U.S. but are uncommon 
(1% of patients) in Europe. The most frequent cardiac 
abnormality is transient atrioventricular block, of varying 
severity, but other arrhythmias, myocarditis, 
endomyocarditis or pericarditis can also occur.. Rarely, 
there may be ocular signs including conjunctivitis during 
the early stages, and uveitis, keratitis, optic neuritis and 
other conditions late. 
After months or years, some patients enter a third, 
chronic stage, which may include acrodermatitis chronica 
atrophicans, neurological abnormalities or chronic 
arthritis. Acrodermatitis chronica atrophicans is a skin 
condition associated with B. afzelii and seen most often on 
the limbs. It usually occurs six months to several years 
after the initial signs. It begins as red or bluish-red 
discoloration of the skin, often accompanied by doughy 
swelling, followed by slow, progressive skin atrophy in 
affected areas, with the skin becoming parchment-like and 
the veins becoming more prominent. Pain, pruritus, 
hyperesthesia or paresthesia, and altered pigmentation are 
possible. Acrodermatitis chronica atrophicans almost 
always occurs in adults, especially women. Late stage 
neurological complications in Europe may include chronic 
progressive meningoencephalitis (in less than 5% of those 
with neurological signs) and multifocal cerebral vasculitis. 
Severe neurological disease is uncommon in North 
America. Chronic cardiac signs have also been associated 
with Lyme disease, but this condition is unproven. Lyme 
disease does not seem to affect pregnancy or cause 
congenital infections. 
Treatment failures are rare with the currently 
recommended antibiotic regimens; however, patients 
treated later may respond more slowly and recovery can 
take weeks or months. A small proportion (less than 10%) 
of patients with arthritis do not respond to antibiotic 
treatment by resolution of the arthritic signs, and have a 
more prolonged course, with persistence for months or 
years. Antibiotic-refractory Lyme arthritis is thought to be 
caused by an autoimmune reaction. A small number of 
patients with neurological signs, arthritis or acrodermatitis 
chronica atrophicans may have residual deficits, especially 
if treatment is delayed until the signs are advanced. 
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Severe, disabling disease is infrequent. Only one human 
death has ever been attributed to Lyme disease. 
Co-infection with another tick-borne disease, 
especially human granulocytic anaplasmosis (formerly 
human granulocytic ehrlichiosis) or babesiosis, can alter the 
clinical signs and response to treatment. 
Chronic Lyme disease and post-Lyme disease 
syndrome 
“Chronic Lyme disease” can be a confusing term, 
because it has been used to describe several different 
groups of patients, including those with persistent 
objective signs of Lyme disease such as arthritis or 
neurological signs; those with nonspecific signs diagnosed 
as Lyme disease; and those with post-Lyme disease 
syndrome. Patients with post-Lyme disease syndrome 
complain of persistent or relapsing nonspecific symptoms 
such as fatigue, headache, sleep disorders, myalgia, 
arthralgia, paresthesias, or difficulty with memory or 
concentration after they have been treated for Lyme 
disease. The cause of post-Lyme syndrome is not known. 
There is no clear evidence that the organism persists in 
this syndrome, and limited numbers of double-blind 
studies have shown no benefit to prolonged antibiotic 
treatment in these patients. Possible causes of post-Lyme 
disease syndrome may include slow resolution after 
treatment, persistent undetected infections, autoimmune 
reactions, post-infective fatigue syndrome (which also 
occurs after a variety of other infections), and concurrent 
diseases or conditions. The number of patients reporting 
symptoms of post-Lyme disease syndrome decreases over 
time.  
Communicability 
There is no evidence that Lyme disease is a 
communicable disease in humans. There are also no reports 
of infections after transfusion with infected blood or contact 
with infected tissues. However, B. burgdorferi s.l. can be 
spread by transfusion in experimentally infected rodents, 
suggesting that this route is at least theoretically possible. 
Laboratory-acquired infections have been reported for the 
related organisms B. recurrentis and B. duttoni, and 
infection control precautions are warranted when working 
with clinical specimens and ticks. 
Diagnostic Tests 
Lyme disease is diagnosed by the clinical signs, 
particularly erythema migrans lesions, in conjunction with 
epidemiology (e.g., exposure to ticks) and laboratory 
testing. 
Serology is used most often for diagnosis, but the 
results must be interpreted with caution and in conjunction 
with clinical signs. The serological diagnosis of Lyme 
disease in many cases of tiredness and vague ill health 
without erythema migrans is controversial. The most 
commonly used screening tests are indirect 
immunofluorescent-antibody (IFA) assays and enzyme 
immunoassays including enzyme-linked immunosorbent 
assay (ELISA) and enzyme-linked fluorescent assay 
(ELFA). EIA, which can be automated, has in many cases 
replaced the IFA test. Because cross-reactions occur in 
screening tests, immunoblotting (Western blotting) is used 
as a confirmatory test with indeterminate or positive 
samples. This two-tier process significantly reduces but 
does not entirely eliminate false positives. A newer test 
based on the C6 portion of the vlsE protein of B. 
burgdorferi is promising. The C6 ELISA may become 
accepted as a one-step test in human medicine in North 
America, but the presence of more than one genospecies 
may limit its utility in Europe. The CSF/serum antibody 
index(AI), used together with signs of inflammation in the 
CSF, is especially helpful in the diagnosis of neurological 
disease caused by B. garinii. The AI response, but not the 
signs of inflammation, can persist for years after recovery.  
Relatively few organisms are found by direct 
examination of clinical specimens. The use of culture in 
diagnostic testing is limited because the procedure is labor-
intensive, the organism is fastidious, and the sensitivity is 
greatest in untreated patients with erythema migrans, who 
can usually be diagnosed by the clinical signs and serology. 
B. burgdorferi s.l. is fastidious and microaerophilic, and it 
must be cultured on enriched bacteriologic media such as 
Barbour-Stoenner-Kelly (BSK) or modified Kelly-
Pettenkofer (MKP) media. Isolation may take up to 12 
weeks, although most cultures may be positive at 1 week. 
B. burgdorferi is a Gram negative spirochete, with a length 
of 10 to 30 μm and a width of 0.2 to 0.5 μm. Spirochetes 
from cultures are motile in freshly prepared slides. 
Organisms can be visualized using dark-field or phase-
contrast microscopy, immunofluorescent microscopy, silver 
staining, Giemsa or acridine orange. They can be confirmed 
as B. burgdorferi sensu lato with specific monoclonal 
antibodies or by detecting nucleic acids with polymerase 
chain reaction (PCR) assays. PCR can also be used to 
identify the genospecies. Culture is most successful early in 
the course of the disease, in patients with erythema migrans 
or early neuroborreliosis. On average, B. burgdorferi s.l. 
can be cultured from 50% of erythema migrans lesions, 
with a range of 20% to 90%. In early studies, the organism 
could be detected in less than 5% of blood samples from 
infected patients, but success rates as high as 40% have 
been reported with high volume plasma culture. It is found 
in less than 10% of CSF samples, and it is detected in only 
1% of joint fluid samples from patients with Lyme arthritis.  
PCR protocols have been developed, and can be 
successfully used on skin biopsies and other samples. The 
sensitivity is highest for erythema migrans and 
acrodermatitis chronica atrophicans lesions, as well as for 
synovial fluid in untreated or partially treated Lyme 
arthritis. The sensitivity of PCR is low for blood or plasma, 
but nucleic acids are sometimes found in the CSF, 
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especially early. PCR can be positive if residual nucleic 
acids from nonviable organisms are present.  
Treatment 
Early treatment with antibiotics such as doxycycline or 
amoxicillin reduces the duration of erythema migrans and 
prevents late stage complications. Doxycycline is used most 
often, since it also is effective for human granulocytic 
ehrlichiosis. Different antibiotics and/or parenteral treatment 
may be recommended for patients with neurological signs or 
cardiac involvement. Treatment failures are rare with the 
currently recommended regiments; however, patients treated 
later in the course of the disease may recover more slowly. 
Anti-inflammatory drugs are used in antibiotic-refractory 
Lyme arthritis. There have been only limited studies on the 
use of antibiotics for post-Lyme disease syndrome; however, 
there was no benefit to continuing antibiotics in the studies 
that have been conducted. Whether the organism can persist 
after antibiotic treatment is uncertain. 
Prevention 
Lyme disease prevention consists of avoiding tick-
infested locations in endemic areas, and preventing tick 
bites with protective footwear, clothing (e.g., long pants 
tucked into the boots, and shirts tucked into the trousers), 
and insect repellents. Ticks may be more visible on light-
colored clothing. People who enter tick habitats should 
check frequently for ticks and remove them as soon as 
possible; gloves are recommended during tick removal. 
Environmental modification to decrease tick exposure 
is more common in North America, where people are often 
exposed around their homes, than in Europe, where 
exposure tends to be occupational or recreational. 
Acaricides and habitat modification, such as the removal of 
leaf litter and brush, can reduce the population of ticks 
around the home. Other approaches in development include 
the use of biological controls such as entomopathogenic 
fungi (e.g., Beauveria bassiana and Metarhizium 
anisopliae), which destroy ticks. Reducing the number of 
deer in the area (e.g. with deer fencing) can be helpful, 
because deer support adult ticks by providing blood meals. 
Studies have also been conducted in treating rodent 
reservoirs or deer with acaricides, or supplying wild rodents 
with permethrin-treated cotton balls, which are used as 
nesting material. 
Postexposure antimicrobial prophylaxis (a single dose 
of doxycycline within 72 hrs) is sometimes given in areas 
where the risk of infection is high and the tick has been 
attached for at least 36 hours. Prophylactic treatment is 
controversial. It is not usually used in Europe. 
A human vaccine was licensed for use in the U.S. in 
1998 but was withdrawn from the market by the 
manufacturer in 2002. Problems included poor demand, 
high cost, the need for a series of 3 vaccinations and 
boosters to maintain high titers, insufficient titers in 
approximately 5% of recipients, and theoretical concerns 
that vaccination might increase the risk of autoimmune 
arthritis. A 2nd-generation vaccine is being studied.  
Morbidity and Mortality 
The incidence of Lyme disease is seasonal and varies 
with vector activity; in the Northern Hemisphere, most cases 
are seen from late spring to summer. The prevalence of Lyme 
disease can be influenced by the ecological niches preferred 
by the tick vectors. For example, Lyme disease is common in 
the eastern and midwestern U.S., but uncommon in the 
Southeast, despite the presence of the vector I. scapularis in 
the latter location. In the Southeast, I. scapularis nymphs are 
much less active in the summer, and the nymphs and larvae 
are also more likely to feed on lizards, which are not usually 
competent reservoir hosts for B. burgdorferi s.s. 
Lyme disease in people is reportable in the U.S., and 
roughly 20,000 cases are reported each year to the Centers 
for Disease Control and Prevention (CDC). Residential 
exposure is common in the U.S., and most cases occur in the 
Northeast, upper Midwest and West Coast. Incidence rates of 
7 to 9.7 per 100,000 population have been reported. 
However, some authors suggest that difficulty in the 
interpretation of serological tests leads to overdiagnosis and 
confusion with other conditions. A significant number of 
patients with chronic conditions seen at Lyme disease referral 
centers do not have this disease.  
In Europe, exposure tends to be the result of 
occupational exposure to ticks or recreation in tick habitats, 
rather than exposure to ticks around the home. Lyme 
disease is not reportable in most European countries. The 
estimated incidence varies from 0.7 cases per 100,000 
population in the UK and 0.6 cases per 100,000 population 
in Ireland to 155 cases per 100,000 population in Slovenia, 
and 100 to 150 cases per 100,000 population in Germany. 
Many cases may not be reported.  
An estimated 5-50% of people infected with B. 
burgdorferi s.l. become ill. In Europe, the seroconversion rate 
is estimated to be 3% to 6% after a tick bite, with overt 
clinical signs in 0.3% to 1.4%. Only some patients with 
erythema migrans and early signs develop late symptoms such 
as Lyme arthritis. In one study, 61% of patients with erythema 
migrans developed neurological, articular or cardiac 
symptoms. Fatal disease is rare, with only one human death 
attributed to Lyme disease, and severe chronic disease is 
uncommon. People can become reinfected, usually with a 
different strain, after approximately 1.5 years. 
Infections in Animals 
Species Affected 
Reservoir hosts 
Reservoir hosts for B. burgdorferi s.l. are considered to 
be  those animals that infect a significant number of the 
ticks that feed on them. The white-footed mouse 
(Peromyscus leucopus) is the main reservoir host for B. 
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burgdorferi s.s. in the eastern U.S. Short-tailed shrews 
(Blarina brevicauda) are also efficient reservoir hosts, and 
eastern chipmunks (Tamias striatus) seem to be important 
in some states. Rodents that have been implicated as 
reservoir hosts in the western U.S. include the white-footed 
mouse (Peromyscus maniculatus), the brush mouse 
(Peromyscus boylii) the western gray squirrel (Sciurus 
griseus), the duskyfooted wood rat (Neotoma fuscipes); and 
the California kangaroo rat (Dipodomys californicus); 
however, a recent molecular analysis suggests that most of 
the Borrelia species carried by the latter two rodents are 
uncharacterized species and only a minority is B. 
burgdorferi s.l.. Additional species of rodents, birds and 
other vertebrates might also be able to act as vectors, 
especially where the main reservoir hosts are absent.  
Animals that have been implicated as reservoir hosts in 
Europe include yellow-necked mice (Apodemus flavicollis), 
striped field mice (A. agrarius) and wood mice (A. 
sylvaticus), and the voles Clethrionomys glareolus and 
Microtus agrestis. Apodemus spp. mice develop persistent, 
low level infections and are efficient in transmitting the 
infection to ticks. Clethrionomys spp. can also transmit the 
infection, but they develop an immune reaction that 
prevents ticks from feeding completely and molting 
successfully. Other species implicated as reservoir hosts 
include shrews, rats, squirrels, dormice, European 
hedgehogs (Erinaceus europaeus), and lagomorphs, 
particularly the brown hare (Lepus europaeus) and the 
varying hare (L. timidus). The reservoir hosts vary with the 
genospecies. B. spielmanii has been associated with 
dormice, and B. afzelii, and B. burgdorferi s.s. are found in 
rodents, but B. garinii and B. valaisiana can also be 
detected in birds. 
The role of birds as reservoirs for Lyme disease has been 
controversial. However, pheasants (Phasianus colchicus), 
and some passerine birds including European blackbirds 
(Turdus merula) and song thrushes (Turdus philomelos) in 
Europe, and Emberiza spp. (a genus in the bunting family) 
and Turdus spp. in Asia are now considered to be 
maintenance hosts for B. garinii in Eurasia and/or B. 
valaisiana in Europe. B. garinii is also linked with seabirds. 
Pheasants do not seem to be infected by B. burgdorferi s.s. in 
significant numbers. In one study, American robins (Turdus 
migratorius), song sparrows (Melospiza melodia) and 
Northern cardinals (Cardinalis cardinalis) were competent 
reservoir hosts for B. burgdorferi s.s. in the laboratory, but 
Eastern towhees (Pipilo erythrophthalmus) and brown 
thrashers (Toxostoma rufum) were not. Gray catbirds 
(Dumatella carolinensis) had some reservoir competence for 
B. burgdorferi s.s. in this experiment, but not in another 
study. 
The role of lizards appears to vary with the species and 
area. The complement proteins in the blood of many lizards 
are highly lytic for B. burgdorferi s.l., and ticks are less likely 
to carry the organism after feeding on these lizards; this 
phenomenon is called zooprophylaxis. In contrast, B. 
lusitaniae seems to be maintained in reptiles in the 
Mediterranean region. Ticks containing this organism may be 
spread by birds, but whether birds can also be competent 
reservoir hosts for B. lusitaniae is unknown. . 
Incidental hosts 
Dogs and wild carnivores may occasionally transmit B. 
burgdorferi s.l. to ticks, but they are not considered to be 
reservoir hosts. A number of cervid species that have been 
investigated, including white-tailed deer (Odocoileus 
virginianus), Columbian black-tailed deer (O. hemionus 
columbianus) and other ‘mule deer,’ roe deer (Capreolus 
capreolus), elk/ red deer (Cervus elaphus), fallow deer 
(Dama dama) and moose (Alces alces) do not transmit the 
bacteria to ticks, although they can be important in 
providing blood meals to adult ticks. Co-feeding, a 
phenomenon where bacteria are transmitted between ticks 
feeding on a host even if the host is not infected, has been 
demonstrated in sheep.  
Naturally occurring Lyme disease has been reported in 
dogs, horses and cattle. Serologic evidence of infection has 
been seen in cats. Dogs, horses, cats, rabbits, mice, 
hamsters, gerbils and guinea pigs can be infected 
experimentally.  
Incubation Period 
The incubation period for arthritis is 2 to 5 months in 
experimentally infected dogs. The incubation period for 
natural infections in animals is unknown. 
Clinical Signs 
The syndromes caused by B. burgdorferi s.l. in animals 
are poorly characterized. Many infections appear to be 
asymptomatic. 
Dogs 
It has been difficult to reproduce Lyme disease in 
experimentally infected dogs. In one study, puppies 
developed transient fever, anorexia and arthritis, sometimes 
accompanied by lymphadenopathy, with the clinical signs 
resolving on their own in 4 days. Some puppies had a few 
recurrent self-limiting episodes of arthritis in the same leg or 
a different leg. Susceptibility seems to decrease with age; 
older puppies were affected less often and the illness resolved 
in 1–2 days, while adult beagles seroconverted  
asymptomatically. Syndromes that have been attributed to B. 
burgdorferi in naturally infected dogs include arthritis, 
kidney disease (Lyme nephritis), cardiac dysfunction and 
neurological signs. With the exception of transient arthritis, 
these syndromes have not been reproducible in the 
laboratory. However, Borrelia antigens have been detected in 
the kidney in cases of kidney disease, and the agent was 
detected in urine culture from at least one dog. One recent 
study suggests that Lyme nephritis may be immune complex 
related.  
The most commonly described syndrome in dogs is 
lameness and arthritis, particularly of the carpal joints. One 
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or a few joints may be involved, and the lameness can be 
intermittent or shift from leg to leg. It may or may not be 
accompanied by swollen, painful joints. Fever, anorexia, 
lethargy/fatigue or lymphadenitis, particularly of the 
prescapular or popliteal nodes, may be seen concurrently. 
The arthritis is usually self-limiting but may become 
chronic or intermittent. 
B. burgdorferi s.l. has also been associated with a form 
of kidney disease called Lyme nephritis or Lyme 
nephropathy. This syndrome is characterized by protein-
losing nephropathy and a unique pathology consisting of 
immune-mediated glomerulonephritis, lymphocytic-
plasmacytic interstitial nephritis and diffuse tubular 
necrosis with regeneration. Some dogs have a history of 
Lyme arthritis or lameness, but this condition also occurs in 
a significant number of dogs that were vaccinated for Lyme 
disease. The clinical signs may be acute or chronic. Most 
dogs have signs of renal failure, which may include 
dehydration, anorexia, lethargy, vomiting, polyuria and 
polydipsia of varying degrees, and weight loss. Vasculitis 
may cause edema or effusions. Hypertension, 
thromboemboli and neurological  signs can also be seen. 
Lyme nephritis usually progresses rapidly and is fatal, but a 
few dogs may live for months. A syndrome of 
glomerulonephritis and interstitial nephritis has also been 
reported in Bernese Mountain Dogs, most of which were 
seropositive for B. burgdorferi s.l..  
A rare cardiac form, characterized by conduction 
abnormalities with bradycardia, and a neurologic form, with 
facial paralysis, seizures or aggression, have also been 
attributed to Lyme disease. Erythema migrans rashes are 
not known to occur. Dogs that are referred to specialists 
with nonresponsive Lyme disease often have other 
illnesses. 
Cats 
Very little is known about the consequences of 
infection in cats. Although 5-47% of cats are seropositive in 
surveys, cases of naturally occurring disease have not been 
published. Conflicting results have been seen in 
experimental infections: in one study, cats remained 
asymptomatic while, in another, they developed fever, 
lethargy, stiffness and arthritis.  
Horses 
In horses, the description of Lyme disease has been 
based mainly on published case reports. Many horses in 
endemic areas are seropositive, and most cases are probably 
subclinical. Clinical signs that have been attributed to B. 
burgdorferi s.l. infection include low-grade fever, arthritis 
with intermittent or shifting lameness and swollen joints, 
myalgia, chronic weight loss and myalgia. Neurological 
signs and skin lesions, as well as rare eye signs (uveitis), 
cardiac disease, hepatitis, laminitis and abortion have also 
been reported. Lymphohistiocytic nodules in the dermis 
have been seen in experimentally infected ponies. Cause 
and effect have been difficult to document in this species.  
Cattle 
Clinical signs that have been attributed to acute Lyme 
disease in cattle include fever, lameness/ stiffness, with or 
without joint swelling, and decreased milk production in the 
acute stage. Erythema, warmth, swelling and 
hypersensitivity  of the skin on the ventral udder were 
reported as the first signs in two cows. These skin lesions 
healed with dark sloughing scabs within a few weeks. 
Laminitis, chronic weight loss, uveitis and abortions have 
also been reported. The illness is said to occur most often in 
first calving heifers. Cattle appear to be relatively resistant 
to experimental infection. In one recent study, calves 
inoculated with the three European genospecies (10 
different Finnish strains) remained asymptomatic. 
Rabbits 
Erythema migrans skin lesions, polyarthritis and 
carditis have been reported in experimentally infected 
rabbits. 
Communicability 
There is little or no evidence that B. burgdorferi s.l. is 
communicable to other animals or humans under natural 
conditions. There is one report of transmission from an 
experimentally infected dog, which excreted spirochetes in 
its urine, to a control animal. However, another study 
reported that susceptible dogs co-housed with infected dogs 
for a year did not seroconvert. 
Diagnostic Tests 
A diagnosis of Lyme disease is usually based on the 
clinical signs, epidemiology (i.e., a history of exposure to 
ticks in an endemic area), elimination of other diseases, 
laboratory data and response to antibiotics. The diagnosis is 
usually presumptive rather than definitive: in most cases, 
laboratory confirmation is by serology, and many 
seropositive animals never develop clinical signs. The 
CBC, blood chemistry, autoimmune panels and radiographs 
are generally normal with the exception of results 
associated with the affected system(s). The joint fluid in 
chronically affected dogs usually consists of a purulent 
exudate, with neutrophils the most abundant cell, and rarely 
contains spirochetes. In acute cases, the volume of joint 
fluid is often too small to sample.  
Serology is useful in supporting the clinical diagnosis. 
Antibodies usually appear in 3-6 weeks in dogs and horses; 
immunoblots may not become diagnostic until 10-12 weeks 
in horses. Because the animal usually seroconverts much 
earlier than the clinical signs appear, paired titers are not 
generally useful. In the past, a two-tier system that consisted 
of screening with ELISA or IFA followed by confirmation 
with immunoblotting was used. In many cases, a single C6-
peptide-based assay has replaced the two-tier serologic 
testing in dogs. An in-house C6 ELISA test, as well as 
quantified C6 antibody testing from diagnostic laboratories, 
are available. The C6 test can also be used in horses, with 
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one study reporting sensitivity of 63% and specificity of 
100% in recently infected horses. Both the C6 test and 
immunoblotting can distinguish vaccinated dogs from dogs 
that have been infected. Antibodies to the C6 antigen occur 
only during natural exposure. Serologic diagnosis is 
complicated by the long incubation period, presence of 
asymptomatic infections, cross-reactions with other 
spirochetes, and persistence of titers for months or years. 
After treatment, titers do not decrease in the IFA, whole cell 
ELISA or immunoblot tests; however, titers in the C6 ELISA 
decrease in experimentally infected dogs, either from 
clearance of the organism or sequestration in immune 
privileged sites.  
Isolation of B. burgdorferi s.l., detection of nucleic acids 
by PCR or antigens by immunohistochemistry, or cytology 
may be possible in some animals, but it is difficult to find the 
organism with any test. Lack of detection does not mean that 
the animal is not infected. Organisms may be detected 
occasionally in the joints (especially synovium), periarticular 
tissue, muscle, CSF, adrenal tissues, lymph nodes, skin, milk 
(cattle) or other sources, including cardiac tissue in heart 
disease and renal tissue in kidney disease. They are rarely 
found in the blood or urine. B. burgdorferi s.l. is fastidious 
and microaerophilic, and must be cultured on enriched 
bacteriologic media such as Barbour-Stoenner-Kelly (BSK) 
or modified Kelly-Pettenkofer (MKP) media. Isolation may 
take up to 12 weeks, although most cultures may be positive 
at 1 week. B. burgdorferi is a Gram negative spirochete, with 
a length of 10 to 30 μm and a width of 0.2 to 0.5 μm. 
Spirochetes from cultures are motile in freshly prepared 
slides. Organisms can be visualized using dark-field or 
phase-contrast microscopy, immunofluorescent microscopy, 
silver staining, Giemsa, or acridine orange stains. They can 
be confirmed as B. burgdorferi sensu lato with specific 
monoclonal antibodies or by detecting nucleic acids with 
PCR. PCR can also be used to identify the genospecies. The 
diagnostic sensitivity of PCR has been reported to be 
comparable to culture in experimentally infected animals. 
Postmortem diagnosis can be made, especially in cases of 
Lyme nephritis, by identifying characteristic lesions and by 
detecting antigens with immunohistochemistry. However, 
other dogs with glomerulonephritis may also have positive 
results in this test.  
Treatment 
Dogs with acute Lyme arthritis usually respond rapidly 
to antibiotics such as amoxicillin or tetracycline derivatives 
(e.g., doxycycline). Acute cases have generally been treated 
for 2 weeks, while dogs with chronic intermittent arthritis 
are usually treated for 4 weeks; however, the optimum 
period and dose have not been established by clinical trials. 
Dogs with chronic arthritis that is not responsive to 
antibiotics may have immune-mediated polyarthropathy, 
and tend to respond to steroids. Longer term antibiotics may 
be used for Lyme nephropathy in dogs. Antibiotics or 
combined antibiotics and anti-inflammatory agents have 
been used for the treatment of Lyme disease in horses. 
Symptomatic treatment, directed toward the affected organ 
system, may also be necessary. Adjunct treatment in canine 
Lyme nephropathy may include  angiotensin-converting 
enzyme inhibitors, low-dose aspirin, omega-3 fatty acids, 
dietary therapy, anti-hypertensive drugs, fluids and 
immunomodulators, but the optimal treatment is still 
unknown. Whether the organism may persist after treatment 
is controversial, but persistent infections, based mainly on 
PCR but also occasionally on skin biopsies, have been 
reported in experimentally infected dogs. 
One author treats Lyme positive dogs that have early 
signs of Lyme nephropathy but appear outwardly healthy 
with doxycycline, angiotensin converting enzyme [ACE] 
inhibitor and low-dose aspirin. These dogs may be stable 
for longer, although it is not certain that this is due to the 
treatment. Some clinicians may monitor seropositive dogs 
for proteinuria as a sign of early Lyme nephropathy. 
Prevention 
Acaricides and tick repellents can be used to help 
prevent tick bites. Animals should also be checked 
frequently (at least daily) for ticks, which should be 
removed as soon as possible. Avoidance of tick habitats, 
such as the woods, reduces exposure. Ticks can especially 
be found in leaf litter, vegetation, overhanging branches, 
and brushy or overgrown lawns. Environmental 
modifications, such as excluding deer from areas near the 
home, can be helpful as for the prevention of Lyme disease 
in people.  
Several different types of Lyme disease vaccines are 
currently available for dogs. The use of these vaccines is 
controversial. Studies of their efficacy are hampered by the 
difficulty in establishing a definitive diagnosis of Lyme 
disease, and uncertainty about the prevalence of the various 
syndromes in seropositive animals. Estimates of vaccine 
efficacy vary from 50% to 85%. The potential contribution 
of autoimmunity to Lyme nephritis raise concerns about 
sensitization from vaccines. Immunity to B. burgdorferi s.l. 
does not persist for long, and annual boosters are 
recommended if vaccines are given. 
Morbidity and Mortality 
Many animals in endemic regions are seropositive. 
Antibodies to Lyme disease can be detected in 25% to 90% 
of healthy dogs in endemic areas, as well as 5% to 47% of 
cats. In the U.S., 14–25% of horses are reported to be 
seropositive in the Northeast, with some studies reporting 
rates as high as 50% in adult horses, and 6–35% in the 
western states. Studies in horses also report seroprevalence 
rates of approximately 26% in Poland, 3-5% in Japan, 8% 
in the Czech Republic, and 49% in Eastern Slovakia. In 
cattle, studies have demonstrated increased numbers of 
seropositive animals after exposure to ticks in the field: 
reported seroprevalence rates were 38% in the spring and 
50% in the summer in Minnesota and Wisconsin; 21% to 
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40% when at pasture, and 36% to 64% after pasturing in 
Slovenia; and 21-40% when going out to pasture and 37-
64% when coming in from pasture in Slovakia. In addition, 
27% of Polish cattle with clinical signs were seropositive, 
and 6% to 34% of cattle in Slovakia had titers, with higher 
seroprevalence rates in older cows and cattle that were lame 
or had swollen joints. One study reported that 50% of gray 
squirrels, 27% of white-tailed deer, 24% of dogs, 23% of 
raccoons, 17% of eastern chipmunks and opossums, and 
10% of white-footed mice were seropositive in eastern 
Connecticut. Within an endemic area, the prevalence of the 
infection can be highly focal. For example, one study 
reported that the seroprevalence was 100% in dogs in one 
small area of Maine, but only 2% in a nearby region.  
Many infections in animals appear to be subclinical. 
Although approximately 75% of young puppies develop 
transient arthritis in laboratory studies, epidemiologic 
studies in endemic areas suggest that approximately 5% or 
less of all infected dogs develop Lyme disease. In one 
study, only 14% of dogs with naturally-occurring, 
Borrelia-specific IgG had any clinical signs that could be 
consistent with Lyme disease. It is not known how many 
dogs that become ill have self-limited illness. Private 
practitioners who use vaccines, as well as those who do 
not, both report they are seeing fewer cases of Lyme 
disease. It is possible that fewer naive dogs are being 
exposed. There is relatively little information on the long-
term outcome of infections in dogs, and the incidence of 
Lyme nephritis is unknown. Whether breed, genetic 
predisposition or other predisposing factors are involved 
is unknown. Bernese Mountain dogs might be more 
susceptible to Lyme disease, but there was no increase in 
the incidence of lameness or signs of renal disease in 
seropositive Bernese Mountain dogs followed for 2.5 to 
3.0 years. The incidence of Lyme disease in horses is 
unknown. In a survey of veterinary practitioners in 
Germany, approximately half reported that they had seen 
Lyme disease in horses, with 1-10 cases seen each year on 
average. 
The mortality rate varies with the form of the disease. 
The most common form of Lyme disease in dogs is 
arthritis, which is not life-threatening. The rare renal form 
is usually fatal, and cardiac disease has been reported to 
cause a life-threatening conduction block. Approximately 
15-25% of treated dogs with arthritis develop recurring or 
chronic signs. 
Post Mortem Lesions      Click to view images 
Dogs 
In dogs with the kidney form, the kidney cortices may 
be diffusely light tan or red-brown, and the cortical surface 
may contain pinpoint red foci. The medulla often bulges on 
cut surface. Subcutaneous, mesenteric, perirenal or 
retroperitoneal edema and ascites may be seen. Pleural 
effusion and pulmonary edema are also common. Less 
common lesions include bilateral parathyroid hyperplasia 
and changes associated with uremia, including 
mineralization of the pleura or left atrium, pulmonary 
mineralization, hemorrhages or mineralization of the gastric 
mucosa or serosa, and bilateral glossal ulcers. Pulmonary 
artery thrombi and acute myocardial necrosis have also 
been reported. Microscopically, the kidney lesions are 
characterized by glomerulonephritis, tubular necrosis and 
diffuse interstitial lymphoplasmacytic inflammation.  
Nonerosive arthritis may be seen in dogs with lameness.  
Cats 
In one study, experimentally infected cats had hepatic 
degeneration, splenic hyperplasia, plasmacytosis of the 
regional lymph nodes and pneumonitis. Cats in another 
study remained asymptomatic. 
Horses 
In experimentally infected ponies, lesions included 
lymphohistiocytic nodules in the dermis, particularly near 
the sites of tick attachment, enlargement of the prescapular 
lymph nodes, and perivascular and perineural lymphocytic 
reactions particularly in the skin, fascia and perisynovial 
membranes.  
Internet Resources 
Centers for Disease Control and Prevention (CDC) 
http://www.cdc.gov/ncidod/dvbid/lyme/index.htm 
Material Safety Data Sheets – Canadian Laboratory Center 
for Disease Control 
http://www.hc-sc.gc.ca/pphb-dgspsp/msds-
ftss/index.html#menu 
The Merck Manual 
http://www.merck.com/pubs/mmanual/ 
The Merck Veterinary Manual 
http://www.merckvetmanual.com/mvm/index.jsp 
Recent Advances in Canine Infectious Diseases 
http://www.ivis.org/advances/Infect_Dis_Carmichael/toc.asp 
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